Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439881 | 1.00 | HSD17B10 (0.33) | HSD17B10OPRD1P2RY6TP53CYP1A2 | |
| SCHEMBL439925 | 1.00 | HSD17B10 (0.33) | HSD17B10OPRD1P2RY6TP53CYP1A2 | |
| SCHEMBL1743117 | 0.86 | HSD17B10 (0.43) | HSD17B10OPRD1P2RY6TP53CYP1A2 | |
| SCHEMBL29402282 | 0.86 | HSD17B10 (0.43) | HSD17B10OPRD1P2RY6TP53CYP1A2 | |
| SCHEMBL663119 | 0.86 | HSD17B10 (0.37) | HSD17B10OPRD1P2RY6TP53CYP1A2 | |
| SCHEMBL20683022 | 0.86 | HSD17B10 (0.37) | HSD17B10OPRD1P2RY6TP53CYP1A2 | |
| SCHEMBL439882 | 0.86 | HSD17B10 (0.37) | HSD17B10OPRD1P2RY6TP53CYP1A2 | |
| SCHEMBL439926 | 0.86 | HSD17B10 (0.37) | HSD17B10OPRD1P2RY6TP53CYP1A2 | |
| SCHEMBL16607421 | 0.86 | HSD17B10 (0.37) | HSD17B10OPRD1P2RY6TP53CYP1A2 | |
| SCHEMBL439879 | 0.84 | HSD17B10 (0.32) | HSD17B10OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064002-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | LEHMANN LUTZ (DE) | 2012-03-15 | — | — | US | disclosed |
| US-20040208828-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic acid and derivatives thereof, process for their production and use for the production of pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040208828-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic acid and derivatives thereof, process for their production and use for the production of pharmaceutical agents | CYP4B1, CYP2B6, UGT2B7 | HSD17B10 494/4885OPRD1 475/4885P2RY6 556/4885 |
| US-20120064002-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | CYP4B1, CYP2B6, UGT2B7 | HSD17B10 524/4885OPRD1 513/4885P2RY6 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.